These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 26362172

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
    Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, Franks R, Pratt D, Forshee RA, MaCurdy T, Worrall C, Howery AE, Kelman J.
    Lancet Infect Dis; 2015 Mar 02; 15(3):293-300. PubMed ID: 25672568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D.
    Value Health; 2011 Mar 02; 14(6):800-11. PubMed ID: 21914499
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC, Tan EC, Su JJ.
    Hum Vaccin Immunother; 2017 Jan 02; 13(1):81-89. PubMed ID: 27624648
    [Abstract] [Full Text] [Related]

  • 11. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT, Crépey P, Pitman RJ, Macabeo B, Chit A, Postma MJ.
    Value Health; 2016 Dec 02; 19(8):964-975. PubMed ID: 27987647
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 02; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E.
    Pharmacoeconomics; 2018 Dec 02; 36(12):1475-1490. PubMed ID: 30251078
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH, Ming WK, Chan PK.
    Hum Vaccin Immunother; 2015 Dec 02; 11(3):564-71. PubMed ID: 25714506
    [Abstract] [Full Text] [Related]

  • 17. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M.
    Value Health; 2007 Dec 02; 10(2):98-116. PubMed ID: 17391419
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G, Gregg M, Poulsen Nautrup B.
    J Med Econ; 2015 Dec 02; 18(9):746-61. PubMed ID: 25903831
    [Abstract] [Full Text] [Related]

  • 19. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
    Tapia MD, Sow SO, Tamboura B, Tégueté I, Pasetti MF, Kodio M, Onwuchekwa U, Tennant SM, Blackwelder WC, Coulibaly F, Traoré A, Keita AM, Haidara FC, Diallo F, Doumbia M, Sanogo D, DeMatt E, Schluterman NH, Buchwald A, Kotloff KL, Chen WH, Orenstein EW, Orenstein LAV, Villanueva J, Bresee J, Treanor J, Levine MM.
    Lancet Infect Dis; 2016 Sep 02; 16(9):1026-1035. PubMed ID: 27261067
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.